CSIMarket
 


Celldex Therapeutics inc   (CLDX)
Other Ticker:  
 

Celldex Therapeutics Inc 's Leverage Ratio

CLDX's quarterly Leverage Ratio and Total Liabilities, Equity growth


Despite a net increase in borrowings by 8.7%, Celldex Therapeutics Inc managed to enhance Leverage Ratio in the forth quarter 2023 to 0.08, falling below the company's typical Leverage Ratio.

Within In Vitro & In Vivo Diagnostic Substances industry Celldex Therapeutics inc achieved the lowest Leverage Ratio in the forth quarter 2023. While Leverage Ratio total ranking has improved so far in the forth quarter 2023 to 40, from total ranking in the third quarter 2023 at 50 .

Explain Leverage Ratio?
Who are CLDX Customers?
What are CLDX´s Total Liabilities?


CLDX Leverage Ratio (Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Equity Change 31.57 % -28.57 % -23.98 % -23.95 % -22.24 %
Y / Y Total Liabilities Change 37.41 % 40.86 % -42.5 % -16.04 % 5.37 %
Leverage Ratio MRQ 0.08 0.14 0.08 0.07 0.08
CLDX's Total Ranking # 40 # 50 # 100 # 21 # 93
Seq. Equity Change 73.95 % -11.1 % -8.32 % -7.19 % -5.56 %
Seq. Total Liabilities Change 8.7 % 54.03 % -0.02 % -17.91 % 11.43 %



Leverage Ratio forth quarter 2023 Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 0
Healthcare Sector # 15
Overall Market # 40


Leverage Ratio Statistics
High Average Low
0.5 0.2 0.05
(Jun 30 2017)   (Sep 30 2021)




Financial Statements
Celldex Therapeutics Inc 's Equity $ 429 Millions Visit CLDX's Balance sheet
Celldex Therapeutics Inc 's Total Liabilities $ 36 Millions Visit CLDX's Balance sheet
Source of CLDX's Sales Visit CLDX's Sales by Geography


Cumulative Celldex Therapeutics Inc 's Leverage Ratio

CLDX's Leverage Ratio for the trailling 12 Months

CLDX Leverage Ratio

(Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Equity TTM Growth 31.57 % -28.57 % -23.98 % -23.95 % -22.24 %
Y / Y Total Liabilities TTM Growth 37.41 % 40.86 % -42.5 % -16.04 % 5.37 %
Leverage Ratio TTM 0.09 0.09 0.08 0.08 0.08
Total Ranking TTM # 49 # 143 # 124 # 159 # 159
Seq. Equity TTM Growth 73.95 % -11.1 % -8.32 % -7.19 % -5.56 %
Seq. Total Liabilities TTM Growth 8.7 % 54.03 % -0.02 % -17.91 % 11.43 %


On the trailing twelve months basis Despite of the net new borrowings of 8.7% during the twelve months period ending in IV Quarter 2023 Celldex Therapeutics Inc has managed to unchanged Leverage Ratio in the IV Quarter 2023 to 0.09, below Celldex Therapeutics Inc 's average Leverage Ratio.
Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the In Vitro & In Vivo Diagnostic Substances industry CLDX recorded the lowest Leverage Ratio. While Leverage Ratio total ranking has improved so far to 43, from total ranking in previous 12 month period at 2.

Explain Leverage Ratio?
Who are CLDX Customers?
What are CLDX´s Total Liabilities?

TTM Leverage Ratio Company Ranking
Within: No.
Within the In Vitro & In Vivo Diagnostic Substances Industry # 0
Healthcare Sector # 1
Within the Market # 40


trailing twelve months Leverage Ratio Statistics
High Average Low
0.43 0.19 0.07
(Dec 31 2017)   (Mar 31 2022)




Companies with similar Leverage Ratio in the quarter ending Dec 31 2023, within In Vitro & In Vivo Diagnostic Substances Industry Leverage RatioDec 31 2023 MRQ Total LiabilitiesDec 31 2023 MRQ Equity
Celldex Therapeutics inc   0.08 $ 36.456  Millions$ 429.171  Millions

Date modified: 2024-02-26T20:57:35+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com